Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7254)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 10, 2015 (publication date) through May 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Arriola E, Taus &, Casadevall D. Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? World J Clin Oncol 2015; 6(4): 45-56 [PMID: 26266101 DOI: 10.5306/wjco.v6.i4.45] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i4/45.htm |
| Number | Citing Articles |
| 1 |
Anne Winther-Larsen, Joan Fledelius, Boe Sandahl Sorensen, Peter Meldgaard. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer 2016; 94: 81 doi: 10.1016/j.lungcan.2016.01.024
|
| 2 |
D. Debieuvre, L. Moreau, M. Coudert, C. Locher, B. Asselain, D. Coëtmeur, C. Dayen, F. Goupil, F. Martin, P. Brun, G. De Faverges, P.-A. Hauss, S. Gally, B. Ben Hadj Yahia, M. Grivaux. Erlotinib en 2e ou 3e ligne pour les cancers bronchiques non à petites cellules sans mutation de l’EGFR : données en vie réelle. Revue des Maladies Respiratoires 2019; 36(6): 649 doi: 10.1016/j.rmr.2019.03.010
|
| 3 |
Carolina Somarriva, Alejandra Fernández, Jorge Candia, Javier Campos, Daniela Albers, Jorge Briceño. Dysregulation and detection methods of EGFR in oral cancer. A narrative review.. Journal of Oral Research 2016; 5(7): 285 doi: 10.17126/joralres.2016.057
|
| 4 |
Anne Winther-Larsen, Joan Fledelius, Christina Demuth, Catharina M Bylov, Peter Meldgaard, Boe S Sorensen. Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology 2016; 9(6): 505 doi: 10.1016/j.tranon.2016.09.003
|